PK/PD Modeling & Simulation

The Highlights in Model-based Drug Development for 2014

Suzanne Minton

As the end of the year draws near, I want to thank all of our customers for letting us be your biosimulation and model based drug development solution provider. We feel honored to be able to play a small, but crucial role in your success in bringing safe and effective drugs to patients. 2014 has […]

Read More
Topics: PK/PD Modeling & Simulation, Scientific Informatics

A Change of Heart at the Cardiac Safety Research Consortium

Christine Garnett

The ICH E14 guidance recommends that all new drugs with systemic bioavailability are assessed for the ability to delay cardiac repolarization as measured by the QT/QTc interval on the surface ECG. For most drugs, this evaluation is performed in the Thorough QT/QTc (TQT) study. Could using model-based approaches during routine early studies influence the current […]

Read More
Topics: PK/PD Modeling & Simulation

5 Updates to the Simcyp Simulator You’ll Be Psyched About

Iain Gardner

The Simcyp™ Population-based Simulator streamlines drug development through the modelling and simulation of physiologically-based pharmacokinetics (PK) and pharmacodynamics (PD) in virtual patient populations. It incorporates numerous databases containing human physiological, genetic and epidemiological information. By integrating this information with in vitro or clinical data, the Simulator can predict PK/PD behavior in ‘real-world’ populations. It can be used to select […]

Read More
Topics: PBPK Modeling & Simulation

Population Modeling Helps Predict the Impact of E-cigarettes on Health

Bill Poland

The Oxford Dictionaries 2014 Word of the Year is “vape” – to inhale and exhale the vapor produced by an electronic cigarette (also known as e-cigarette or e-cig) or similar device. This choice reflects the meteoric rise in e-cig popularity. E-cigs, which deliver nicotine without carcinogenic tar, hold the promise to save the lives of […]

Read More
Topics: Uncategorized